Shaking off the working week! What's on the agenda for the weekend? 📷 by KonstantinKolosov via… https://t.co/fSyxq53H6P
RT @placeitapp: Making a #YouTube banner for your channel is easy with Placeit's #bannermaker! Make your own in sec… https://t.co/0X22tX3wtm
Our Chief People Officer @MRidsdale16 joined @benjaminlaw and @raejohnston on @tsushow to discuss all things Cultu… https://t.co/uszxz0qicU
Lycotec has developed and a new liver-targeting delivery technology for orally administered drugs, vitamins, and other bioactive molecules.
This technology could benefit those drugs which particular targeting liver specific biochemical pathways, for example statins.
Results of the proof of concept pharmaco-dynamic clinical trial, for our proprietary formulation LycoStatinTM, containing 20 mg of Simvastatin are presented on the figure below.
Lycotec technology promotes selective delivery of drug molecules to the liver, and consequently reduces their presence, and hence side-effects, in extra-hepatic tissues.
The technology can be applied for other small molecules as well as for peptides and some proteins.
Lycotec technologies in the media both in the UK and Internationally